HLA class I--restricted CD8^+^ CTL responses have been associated with viral containment during acute infection and are thought to contribute to the establishment of viral setpoint in the chronic stages of infection ([@bib6]; [@bib32]; [@bib30]; [@bib48]; [@bib8]; [@bib41]; [@bib53]). Aside from CTL epitopes located in proteins encoded by HIV open reading frames (ORFs), recent data point toward the existence of epitopes in protein sequences encoded by frameshifted HIV ([@bib14]) and SIV nucleotide sequences ([@bib36]). Such alternative reading frame (ARF)--encoded epitopes have been reported in a variety of human diseases, including influenza infection, malignancies, and autoimmunity ([@bib12]; [@bib55]; [@bib13]; [@bib43]; [@bib42]; [@bib46]; [@bib47]), but they may occur at particularly high frequency in HIV and other retroviral pathogens that show frequent nucleotide deletions or insertions in their genome. Early studies in mouse AIDS and the recent reports in HIV and SIV infections suggest that immune responses mounted against such frameshifted epitopes could potentially contribute to viral control in vivo ([@bib38]; [@bib27]). Indeed, CTLs targeting an HLA-B\*07--restricted ARF epitope, first identified in HLA-B\*07 transgenic mice, were able to recognize HIV-infected cells and kill peptide-pulsed antigen-presenting cells ([@bib14]). Moreover, ARF epitope--specific CTLs inhibited SIV replication in autologous infected cells in vitro and appeared to select for viral escape variants that abrogated the epitope binding to Mamu-B\*17 in vivo ([@bib59]; [@bib36]).

The analysis of immune escape mutations in HIV-infected individuals expressing specific HLA class I alleles has allowed for the identification of HLA class I allele--specific "footprints," which reflect the accumulation of particular HIV sequence polymorphisms in individuals carrying or lacking a specific HLA class I allele ([@bib40]; [@bib35]; [@bib2]; [@bib44]; [@bib11]). The presence of such HLA footprints is thought to represent direct evidence for in vivo immune selection pressure on the virus by the host cellular immune response. Importantly, these footprints have also facilitated the identification of novel CTL epitopes in HIV coding sequences, although the presentation of individual epitopes on several HLA alleles may complicate the interpretation ([@bib2]; [@bib19]).

Little is known about the potential in vivo relevance of ARF epitopes and how responses against such targets could affect viral evolution. To address this, we assessed the presence and frequency of HLA-associated viral polymorphisms that were statistically significant in one or more ARFs but not in the primary ORF (e.g., synonymous changes) in a large cohort of 765 untreated, chronically HIV-infected individuals ([@bib9], [@bib10]). Our data indicate that cellular immune responses to ARF-encoded sequences are not infrequent in HIV-infected individuals and that these responses can inhibit viral replication in vitro. Their in vivo relevance is further reflected by the identification of HLA class I allele--specific associations with particular viral polymorphisms that did not affect the amino acid sequence in the original reading frame yet represent effective escape from ARF epitope--specific CTL populations.

RESULTS
=======

Population-level HLA-associated viral polymorphisms in ARF sequences indicate CTL-mediated immune pressure
----------------------------------------------------------------------------------------------------------

To identify ARF-directed T cell responses and to assess population-wide immune selection pressure mediated by these responses, HIV gag, pol, and nef sequences from a cohort of 765 individuals were analyzed for HLA allele--associated sequence polymorphisms in ARFs ([@bib9], [@bib10]). All nucleotide sequences were initially translated in the putative +1 and +2 reading frames and analyzed for HLA class I allele--associated viral polymorphisms, as previously described ([@bib15]). A correction for multiple comparisons using a q-value approach ([@bib52]) was applied, and associations with a false discovery rate of 20% or lower (q \< 0.2) were included. A total of 64 HLA-associated viral polymorphisms unique to the ARF were identified in gag (29 associations), pol (27 associations), and nef (8 associations). Of these, 12, 18, and 7 were derived from +1 shifted reading frames and 17, 9, and 1 were derived from +2 shifted sequences, respectively ([Table I](#tbl1){ref-type="table"}). It is important to note that the HLA-associated polymorphisms listed in [Table I](#tbl1){ref-type="table"} were not reflected in the coding sequence of the HIV protein, and these associations are unique to the +1 and/or +2 ARF only. Indeed, our method also identified HLA-associated polymorphisms in the coding sequence, which resulted in (statistically significant) nonsynonymous substitutions in the +1 and +2 frames, but these were excluded from further analysis as we conservatively assumed that these imprints were driven by immune responses to the known HIV proteins. Furthermore, all HLA-associated polymorphisms in ARF that had an HLA association with any HLA allele within ±2 amino acids in the corresponding primary coding sequence were also excluded from analysis (for a complete list of imprints see [Table S1](http://www.jem.org/cgi/content/full/jem.20091808/DC1)).

###### 

HLA-associated viral polymorphisms in the +1 and +2 ARFs

  RF   Protein     Association   HLA   Pos HXB2   aa   p-value         q-value         Dist
  ---- ----------- ------------- ----- ---------- ---- --------------- --------------- ------
  +1   Gag         Adapted       C05   12         T    4.76 × 10^−4^   1.91 × 10^−1^   14
  +1   Gag         Nonadapted    A03   45         Q    1.47 × 10^−4^   1.02 × 10^−1^   13
  +1   Gag         Adapted       A29   86         F    1.07 × 10^−4^   7.94 × 10^−2^   5
  +1   Gag         Adapted       B40   99         R    3.42 × 10^−4^   1.73 × 10^−1^   4
  +1   Gag         Adapted       B08   132        T    3.84 × 10^−4^   1.73 × 10^−1^   5
  +1   Gag         Nonadapted    A23   138        S    2.04 × 10^−4^   1.23 × 10^−1^   8
  +1   Gag         Adapted       C06   168        S    8.89 × 10^−5^   6.79 × 10^−2^   20
  +1   Gag         Adapted       B57   253        T    4.41 × 10^−4^   1.85 × 10^−1^   11
  +1   Gag         Nonadapted    B57   253        I    4.43 × 10^−4^   1.85 × 10^−1^   11
  +1   Gag         Adapted       B48   321        Y    3.08 × 10^−4^   1.64 × 10^−1^   9
  +1   Gag         Nonadapted    B48   321        C    3.08 × 10^−4^   1.64 × 10^−1^   9
  +1   Gag         Nonadapted    B52   499        H    4.07 × 10^−4^   1.76 × 10^−1^   17
  +1   pol (pro)   Adapted       A01   73         A    4.26 × 10^−6^   3.55 × 10^−3^   10
  +1   pol (RT)    Adapted       B07   25         P    2.87 × 10^−4^   1.18 × 10^−1^   10
  +1   pol (RT)    Adapted       A01   53         K    2.17 × 10^−4^   9.2 × 10^−2^    18
  +1   pol (RT)    Adapted       B46   151        K    1.49 × 10^−4^   7.66 × 10^−2^   7
  +1   pol (RT)    Nonadapted    B46   151        R    1.53 × 10^−4^   7.66 × 10^−2^   7
  +1   pol (RT)    Nonadapted    B40   258        R    5.1 × 10^−4^    1.74 × 10^−1^   13
  +1   pol (RT)    Adapted       B40   258        K    5.1 × 10^−4^    1.74 × 10^−1^   13
  +1   pol (RT)    Adapted       B58   271        M    8.2 × 10^−5^    4.93 × 10^−2^   6
  +1   pol (RT)    Adapted       B14   305        R    5.63 × 10^−4^   1.84 × 10^−1^   8
  +1   pol (RT)    Nonadapted    B14   305        K    5.63 × 10^−4^   1.84 × 10^−1^   8
  +1   pol (RT)    Adapted       C06   326        \*   5.75 × 10^−4^   1.86 × 10^−1^   3
  +1   pol (RT)    Nonadapted    B27   356        E    4.39 × 10^−4^   1.58 × 10^−1^   11
  +1   pol (int)   Adapted       B44   153        L    1.15 × 10^−4^   6.49 × 10^−2^   3
  +1   pol (int)   Adapted       A03   240        N    2.4 × 10^−4^    10^−1^          6
  +1   pol (int)   Nonadapted    A03   240        S    3.22 × 10^−4^   1.26 × 10^−1^   6
  +1   pol (int)   Nonadapted    A03   241        F    1.78 × 10^−8^   3.55 × 10^−5^   7
  +1   pol (int)   Adapted       A03   241        S    3.06 × 10^−5^   2.03 × 10^−2^   7
  +1   pol (int)   Nonadapted    A23   241        F    3.56 × 10^−4^   1.33 × 10^−1^   7
  +1   Nef         Nonadapted    B13   24         S    4.34 × 10^−4^   1.02 × 10^−1^   3
  +1   Nef         Adapted       C05   28         M    6.29 × 10^−4^   1.3 × 10^−1^    4
  +1   Nef         Adapted       A02   28         P    9.83 × 10^−4^   1.74 × 10^−1^   4
  +1   Nef         Nonadapted    B18   58         \*   4.28 × 10^−4^   1.02 × 10^−1^   4
  +1   Nef         Nonadapted    B44   146        Y    8.49 × 10^−4^   1.6 × 10^−1^    3
  +1   Nef         Adapted       C15   158        K    3.01 × 10^−4^   7.77 × 10^−2^   3
  +1   Nef         Adapted       A24   177        K    1.41 × 10^−4^   3.98 × 10^−2^   3
  +2   Gag         Adapted       C05   12         L    4.76 × 10^−4^   1.8 × 10^−1^    14
  +2   Gag         Nonadapted    A03   45         S    5.19 × 10^−5^   4.08 × 10^−2^   13
  +2   Gag         Nonadapted    C06   53         S    5.29 × 10^−5^   4.08 × 10^−2^   5
  +2   Gag         Adapted       B40   99         G    3.42 × 10^−4^   1.51 × 10^−1^   4
  +2   Gag         Adapted       A68   123        R    9.03 × 10^−6^   1.16 × 10^−2^   4
  +2   Gag         Nonadapted    A23   138        P    1.82 × 10^−4^   1.04 × 10^−1^   8
  +2   Gag         Adapted       C06   168        H    8.89 × 10^−5^   6.22 × 10^−2^   20
  +2   Gag         Nonadapted    B49   183        F    1.47 × 10^−4^   9.18 × 10^−2^   28
  +2   Gag         Adapted       B57   253        P    4.61 × 10^−4^   1.8 × 10^−1^    11
  +2   Gag         Nonadapted    B57   253        S    4.61 × 10^−4^   1.8 × 10^−1^    11
  +2   Gag         Adapted       C02   272        S    2.31 × 10^−4^   1.15 × 10^−1^   4
  +2   Gag         Adapted       B48   298        S    5.09 × 10^−4^   1.9 × 10^−1^    4
  +2   Gag         Adapted       B48   321        I    2.32 × 10^−4^   1.15 × 10^−1^   9
  +2   Gag         Nonadapted    B53   465        G    1.18 × 10^−5^   1.29 × 10^−2^   12
  +2   Gag         Adapted       B52   499        A    1.95 × 10^−5^   1.88 × 10^−2^   17
  +2   Gag         Nonadapted    B51   499        T    7.49 × 10^−5^   5.41 × 10^−2^   17
  +2   Gag         Nonadapted    B52   499        T    9.38 × 10^−5^   6.37 × 10^−2^   17
  +2   pol (pro)   Adapted       A01   73         H    4.26 × 10^−6^   6.86 × 10^−3^   10
  +2   pol (pro)   Nonadapted    A01   73         Y    2.61 × 10^−4^   1.63 × 10^−1^   10
  +2   pol (RT)    Adapted       B07   25         L    2.87 × 10^−4^   1.75 × 10^−1^   10
  +2   pol (RT)    Adapted       A01   53         K    2.18 × 10^−4^   1.49 × 10^−1^   18
  +2   pol (RT)    Adapted       B58   271        C    6.64 × 10^−5^   6.5 × 10^−2^    6
  +2   pol (int)   Adapted       A03   240        T    2.4 × 10^−4^    1.53 × 10^−1^   6
  +2   pol (int)   Nonadapted    A03   240        A    2.41 × 10^−4^   1.53 × 10^−1^   6
  +2   pol (int)   Nonadapted    A03   241        S    1.78 × 10^−8^   4.84 × 10^−5^   7
  +2   pol (int)   Adapted       A03   241        P    3.08 × 10^−5^   3.24 × 10^−2^   7
  +2   Nef         Adapted       B40   157        \*   5.17 × 10^−4^   1.25 × 10^−1^   4

RF indicates the reading frame relative to the regular coding frame of the respective protein. For associations, adapted forms are amino acids significantly enriched in the presence of the HLA allele in question (and vice versa), whereas nonadapted forms (also commonly called wild-type or susceptible forms) are amino acids significantly depleted in the presence of the HLA allele in question (and vice versa). HLA indicates the HLA allele for which the association was observed. Pos HXB2 indicates the amino acid position in the corresponding HXB2 primary reading frame sequence (Leitner et al., 2005). aa indicates the amino acid for which the HLA-associated polymorphism was observed. dist indicates the distance (in amino acids) to the next HLA-associated viral polymorphism (to any HLA allele) in the primary ORF. Asterisks indicate stop codons.

According to a recent publication that introduces a consistent nomenclature of HLA-associated viral polymorphisms ([@bib11]), the associations identified in this study are referred to as adapted and nonadapted forms. Adapted forms (also commonly called escape variants) are amino acids significantly enriched in the presence of the HLA allele in question (and vice versa). Nonadapted forms (also commonly called wild-type or susceptible forms) are amino acids significantly depleted in the presence of the HLA allele in question (and vice versa).

Peptides spanning regions of ARF sequence polymorphisms are targeted by HIV-infected individuals
------------------------------------------------------------------------------------------------

To investigate if the observed HLA-associated polymorphisms could in fact be the result of viral adaptation to CTL-mediated immune pressure on alternative-frame HIV peptides, in vitro T cell responses to ARF peptides spanning the region of the associations were assessed. Peptides were synthesized to either contain the identified imprint in the center of two overlapping peptide (OLP) sequences (between 13 and 20 amino acids in length, and overlapping by 9--10 amino acids) or as short (9--12 amino acids long) predicted CTL epitopes using a recently developed epitope prediction algorithm ([@bib25]), and were then tested by ex vivo IFN-γ ELISPOT assay using PBMCs from untreated, chronically HIV-infected individuals. Peptides included 9 sequences from the +1 ORF and 12 from the +2 ORF, covering 10, 8, and 2 regions of imprints in gag, pol, and nef, respectively ([Table II](#tbl2){ref-type="table"}). Responses were observed in 21 out of 85 HIV-infected individuals and 0 out of 32 HIV-negative individuals tested (P = 0.001 using Fisher's exact test), indicating that responses are HIV specific ([Fig. 1 A](#fig1){ref-type="fig"}). Of note, there was no statistical difference in HLA class I allele representation between the HIV-infected and -uninfected individuals, indicating that the HIV-negative group was a suitable control population ([Tables S2 and S3](http://www.jem.org/cgi/content/full/jem.20091808/DC1)).

###### 

HLA imprints and regions tested

  RF   Protein     HLA   aa   Pos   Association   p-value         q-value         Dist   Region of imprint
  ---- ----------- ----- ---- ----- ------------- --------------- --------------- ------ --------------------------------------
  +1   gag         B52   H    499   Nonadapted    4.07 × 10^−4^   1.76 × 10^−1^   17     \*LPSDHSLATTPR**H**\*
  +1   pol (RT)    B07   P    124   Adapted       2.87 × 10^−4^   1.18 × 10^−1^   10     \*SQEWMAQKLNNG**H**\*
  +1   pol (RT)    A03   F    142   Nonadapted    1.78 × 10^−8^   3.55 × 10^−5^   7      GTAEIHFGKD[QQS**F**SGKVK]{.ul}GQ
  +1   pol (RT)    B46   K    149   Adapted       1.49 × 10^−4^   7.66 × 10^−2^   7      RHQGLDISTMCFH**R**DGKDHQQYSKVA
  +1   pol (RT)    B40   R    258   Nonadapted    5.1 × 10^−4^    1.74 × 10^−1^   13     \*CCQKKTAGLSMTY**R**S\*
  +1   pol (Int)   A03   N    240   Adapted       2.4 × 10^−4^    10^−1^          6      TGTAEIHFGKDQQ**S**FSGKVKGQ
  +1   pol (Int)   A03   S    240   Nonadapted    3.22 × 10^−4^   1.26 × 10^−1^   6      TGTAEIHFGKDQQ**S**FSGKVKGQ
  +1   nef         A24   K    177   Adapted       1.41 × 10^−4^   3.98 × 10^−2^   3      \*ASMGWMTR**R**KKC\*
  +1   nef         C15   K    158   Adapted       3.01 × 10^−4^   7.77 × 10^−2^   3      \*KRPM**[Q]{.ul}**[ERTTACY]{.ul}TL\*
  +2   gag         C05   L    12    Nonadapted    4.76 × 10^−4^   1.8 × 10^−1^    14     GCESVSIKRGR**I**R\*
  +2   gag         A03   S    45    Nonadapted    5.19 × 10^−5^   4.08 × 10^−2^   13     TYSMGKQGARTIR**S**\*
  +2   gag         C06   S    53    Nonadapted    5.29 × 10^−5^   4.08 × 10^−2^   5      SWPVRN**S**RRL
  +2   gag         A68   R    123   Adapted       9.03 × 10^−6^   1.16 × 10^−2^   4      \*HR**K**QQPGQPKLPYSAE
  +2   gag         B49   F    183   Nonadapted    1.47 × 10^−4^   9.18 × 10^−2^   28     HVFSIIRRSHPTR**F**KHHAKHSGGTSSS
  +2   gag         B51   T    499   Nonadapted    7.49 × 10^−5^   5.41 × 10^−2^   17     SFPQITLWQRPLV**T**\*
  +2   gag         B52   T    499   Nonadapted    9.38 × 10^−5^   6.37 × 10^−2^   17     SFPQITLWQRPLV**T**\*
  +2   gag         B53   G    465   Nonadapted    1.18 × 10^−5^   1.29 × 10^−2^   12     TRANSPTRRELQV**W**GRDNNSLSEAGAD
  +2   pol (Pro)   A01   H    73    Nonadapted    4.26 × 10^−6^   6.86 × 10^−3^   10     \*S[YR**Y**SISRTY]{.ul}TCQHNWK
  +2   pol (RT)    B07   L    25    Nonadapted    2.87 × 10^−4^   1.75 × 10^−1^   10     \*TMA**I**DRRKNKSISRNLY
  +2   pol (Int)   A03   S    241   Nonadapted    1.78 × 10^−8^   4.84 × 10^−5^   7      GQQRSTLERTSKA**S**LER\*

HLA indicates the HLA allele for which the association was observed. aa indicates the amino acid for which the HLA-associated polymorphism was observed. Pos indicates the amino acid position in the corresponding HXB2 primary reading frame sequence ([@bib34]). For associations, adapted forms are amino acids significantly enriched in the presence of the HLA allele in question (and vice versa), whereas nonadapted forms are amino acids significantly depleted in the presence of the HLA allele in question (and vice versa). Dist indicates the distance (in amino acids) to the next HLA-associated viral polymorphism (to any HLA allele) in the primary ORF. Region of imprint shows the sequences surrounding the imprint (bold). In cases where predicted epitopes were tested, the respective sequence is underlined. \*, stop codon.

![**Magnitude and breadth of CTL responses to frameshift-derived peptides.** (A--C) 85 HIV-infected individuals and 32 HIV-negative controls were tested for CTL responses in ex vivo IFN-γ ELISPOT using fresh PBMCs. 21 out of 85 patients displayed a CTL response to at least one of the peptides tested. Peptides were exclusively recognized in HIV-infected individuals. (A) The number of peptides targeted by each individual tested is shown (A). Magnitude of responses in the IFN-γ ELISPOT is expressed as SFCs/10^6^ PBMCs. The horizontal bar represents the median magnitude (B). The frequency and sequence of the responses to individual peptides are shown. All peptides tested and the respective number of patients mounting a CTL response are indicated. The 17mer GQQRSTLERTSKASLER (GR17) was recognized by 10 out of the 85 individuals tested (C).](JEM_20091808_RGB_Fig1){#fig1}

Among the 21 subjects with responses, 27 peptide-specific activities were seen with a median magnitude of 140 spot-forming cells (SFCs)/10^6^ PBMCs (range: 50--820 SFCs/10^6^ PBMCs; [Fig. 1 B](#fig1){ref-type="fig"}). Responses in seven individuals were reconfirmed by intracellular cytokine staining using flow cytometry and were in all cases mediated by CD8 T cells (not depicted). The frequency of individuals with detectable responses (24.7%) is comparable to that seen to first-frame responses to HIV protease, Vpu, Rev, Tat, and Vif (11--40% of responders, based on protein-specific peptide sets ranging from 9 to 24 OLPs). These proteins are consistently among the less frequently targeted HIV proteins ([@bib18]; [@bib61]) that elicit responses of comparable magnitude (all P \> 0.05; [@bib61]). Thus, although of lower magnitude and frequency than responses to dominant targets such as HIV Gag, RT, and Nef, responses to ARF were well above stringent assay backgrounds, also reflected by the fact that no spurious responses were seen in HIV-uninfected subjects ([Fig. 1 A](#fig1){ref-type="fig"}). Interestingly, the responses to the tested predicted ARF epitopes and longer ARF peptides did not occur exclusively in the individuals expressing the HLA allele for which an imprint was present in that region. Although these situations were less frequent (19 out of the 27 responses detected were observed in subjects expressing either the imprint allele \[*n* = 8\] or at least an HLA supertype--matched allele \[*n* = 11\]), 8 responses were unexpected based on the HLA type of the tested individual. The recently described extensive HLA promiscuity even among optimally defined CTL epitopes and the fact that the in vitro testing was based on longer peptide sequences that may contain multiple epitopes presented by different HLA alleles likely explain the detection of these responses in the absence of the imprint HLA alleles ([@bib23]; [@bib17]; [@bib19]). Among the reactive peptides, three regions (four peptides) were targeted by \>1 out of the 21 reactive individuals ([Fig. 1 C](#fig1){ref-type="fig"}). In particular, the GQQRSTLERTSKASLER (GR17 peptide) sequence was recognized by 10 individuals of whom all but 1 expressed either HLA-A\*03 or an HLA-A\*03 supertype allele ([Table III](#tbl3){ref-type="table"}; [@bib51]). The median magnitude of the response was 185 SFCs/10^6^ PBMCs (range: 70--640 SFCs/10^6^ PBMCs). This peptide spanned the site of the strongest imprint identified in this study (P = 1.78 × 10^−8^; q = 0.000048), which was indeed associated with an adapted polymorphism in the context of HLA-A\*03. As indicated in [Table II](#tbl2){ref-type="table"}, individuals expressing the HLA-A\*03 allele were significantly less likely to have a serine residue at position 241 in the +2 frameshifted integrase sequence compared with HLA-A\*03--negative individuals. The HLA types of all patients with a response to GR17 are summarized in [Table III](#tbl3){ref-type="table"}. To rule out that the observed HLA-A\*03 imprint originated from immune pressure on epitopes derived from other reading frames (i.e., the original Pol sequence or its +1 ARF), responses in HLA-A\*03--expressing individuals to these regions were assessed. Overall, only one HLA-A\*03--expressing individual mounted a response to the corresponding peptide in ARF +1. In addition, in listings from the Los Alamos HIV immunology database and in datasets from two clade B--infected cohorts with a total of \>600 comprehensively tested individuals, no evidence emerges that the corresponding region in the original frame (i.e., HIV integrase 241) contains an HLA-A\*03 (supertype)--restricted epitope (unpublished data; [@bib18]; [@bib61]). Similarly, available population-based studies of HLA footprinting provide no evidence of an A\*03-associated polymorphism in the coding sequence ([@bib44]; [@bib11]). Collectively, these data suggest that responses to the peptide encoded by the +2 ARF, not the integrase coding sequence peptide, were driving the observed imprint.

###### 

HLA types and clinical characteristics of individuals recognizing the GQQRSTLERTSKASLER (GR17) peptide

  Patient   HLA-A               HLA-B       HLA-Cw      SFCs/10^6^ PBMCs   CD4 count   VL        Clinical course
  --------- ------------------- ----------- ----------- ------------------ ----------- --------- -------------------
  1         0201/1101           0702/1401   0702/0802   190                393         6,270     Chronic untreated
  2         **0301**/**0301**   0702/5101   0702/1402   70                 147         165,995   Chronic untreated
  3         0201/**0301**       3501/4501   ND /1601    140                371         216,000   Chronic untreated
  4         **0301**/2501       1801/3501   0401/1203   410                286         5,322     Chronic untreated
  5         2601/7401           3701/4901   0602/0701   240                109         7,310     Chronic untreated
  6         2902/3201           4402/4403   0501/1601   610                582         8,450     Chronic untreated
  7         0201/**0301**       5101/5101   0303/1502   640                791         74        Controller
  8         **0301**/3001       4201/5802   0602/1700   110                344         2,650     Chronic untreated
  9         0101/3301           0801/1402   0701/0802   80                 540         156,000   Chronic untreated
  10        **0301**/1101       0702/4402   0501/0702   180                553         13,100    Chronic untreated

SFCs/10^6^ PBMCs indicates the magnitude of IFN-γ ELISPOT responses. CD4 counts are indicated in cells per microliter. VL indicates the viral load in RNA copies per milliliter. Clinical course indicates if a patient is chronically HIV infected and untreated or is a spontaneous controller of HIV infection in the absence of any HIV-specific treatment. A\*03 alleles are bolded to highlight which patients were expressing A\*03. ND, not done.

Identification of the optimal HLA-A\*03 ARF epitope and its associated escape mutation
--------------------------------------------------------------------------------------

To further describe the recognized epitope within the GR17 peptide and to evaluate whether the observed imprint in ARF +2 was affecting functional CTL recognition, standard epitope mapping analyses using serial truncations of the GR17 peptide were performed ([Fig. 2](#fig2){ref-type="fig"}). Binding motif analysis suggested the presence of two potentially A\*03-restricted epitopes, RTSKASLER (RR9) and RSTLERTSK (RK9; [Fig. 2 B](#fig2){ref-type="fig"}). As shown in [Fig. 2 C](#fig2){ref-type="fig"}, the optimal epitope mapped to the 9mer sequence RR9. The highly statistically significant HLA-A\*03--associated ARF polymorphism observed at the population level mapped to position 6 (underlined) of this epitope (RTSKA[P]{.ul}LER), suggesting abrogation of TCR recognition as a possible mechanism of escape ([@bib50]; [@bib45]). Subsequent HLA restriction analysis using partly HLA-matched APCs and RR9-specific T cell lines (TCLs) confirmed the restriction of this epitope by HLA-A\*03 ([Fig. 2 D](#fig2){ref-type="fig"}). To test whether sequence mutation within the RR9 epitope affected CTL recognition, the most common variants (minimal frequency of 2% in the sequences of the 765 individuals included in the population-based viral polymorphism analysis) were synthesized and tested for their ability to elicit T cell activity in RR9 responders ([Fig. 3](#fig3){ref-type="fig"}). The three tested variants were more common in A\*03-positive individuals, with two of them producing a significant HLA-associated imprint in the initial analysis: RTSKA[P]{.ul}LER (A\*03-RPR9; P = 3.08 × 10^−5^; q = 0.0324), RTSK[T]{.ul}SLER (A\*03-RTR9; P = 2.4 × 10^−4^; q = 0.153), and RTSKA[A]{.ul}LER (A\*03-RAR9; [Fig. 3 A](#fig3){ref-type="fig"}). Recognition of these epitope variants was then tested in the context of five HLA-A\*03--expressing subjects. Neither of the subjects tested recognized the A\*03-RPR9 or the A\*03-RTR9. In contrast, two of the HLA-A\*03--positive and the one HLA-A\*03--negative but HLA-A\*74--expressing individual mounted a detectable response to the A\*03-RAR9 variant. Thus, the amino acid change at position 6 from a serine to an alanine (which did not appear as a common variant in the imprint analysis; Table S1) is only variably associated with escape from recognition in the HLA-A3 context ([Fig. 3 B](#fig3){ref-type="fig"}).

![**Epitope mapping of A\*03-RTSKASLER.** HIV sequencing and analysis for HLA-associated polymorphisms revealed that viruses isolated from A\*03-positive patients show a common S→P change at position 241 in the +2 ARF relative to integrase. The amino acid sequence of this region in all three reading frames (RF1--3) and the location relative to the protein-encoding HIV genome (HXB2) are displayed. An A\*03-associated imprint was also observed in the +1 ARF at the same position (A\*03 is associated with an S instead of F at that position). 10 out of 85 individuals tested mounted a response to the region in the +2 ARF versus only 1 individual to the +1 ARF region. The shaded sequence indicates the newly identified A\*03 epitope (A). The optimal epitope length of the GQQRSTLERTSKASLER (GR17) peptide was determined using sequential peptide truncations. IFN-γ ELISPOT responses at 100 and 10 µg/ml are displayed (B). Functional avidity was determined using serial 10-fold dilutions of the peptides ranging from 100 to 0.0001 µg/ml. The shortest peptide with the lowest SD50% was considered the optimal epitope (RTSKASLER; RR9; C). Partly HLA-matched BCLs were used for HLA restriction analyses and responses were determined with intracellular cytokine staining. Bars represent the percentage of IFN-γ--positive CD8^+^ CTLs (left), and the histogram shows IFN-γ positivity of CD3^+^ CD8^+^ gated cells (right). RR9 peptide--loaded BCLs only matched in the A\*03 allele (orange and red lines) coincubated with an RR9-specific effector TCL resulted in an IFN-γ response comparable to incubation with peptide-loaded autologous BCLs (gray-shaded area). Peptide-loaded BCLs matched in the other alleles did not induce IFN-γ production (gray lines; D). One out of at least three independent experiments is shown.](JEM_20091808_RGB_Fig2){#fig2}

![**Commonly occurring HIV variants can escape recognition.** (A and B) Viral variants of the A\*03-RR9 epitope occurring with \>2% frequency in the British Columbia cohort were identified. Frequency of the analyzed variants in A\*03-negative (black bars) and -positive (white bars) individuals are displayed (A). Recognition of the consensus sequence peptide and the three variants was assessed in A\*03-RR9 responders. All five A\*03-positive individuals tested recognized the consensus sequence (black bars) but not the variants with the S→P change at amino acid position 6 (RTSKA[P]{.ul}LER) or the A→S change at position 5 (RTSK[T]{.ul}SLER) of the epitope, suggesting that these variants are escape forms (gray bars). In contrast, two of the A\*03-positive and one A\*74-positive individuals recognized the S→A variant (RTSKA[A]{.ul}LER; white bar) as well (B).](JEM_20091808_GS_Fig3){#fig3}

A\*03-RR9--specific CTLs inhibit viral replication in vitro
-----------------------------------------------------------

To demonstrate the expression and presentation of RR9 in infected cells and that the observed polymorphisms were effective immune escape variants, we engineered multiple viral constructs and assessed them in in vitro inhibition assays. We introduced different point mutations on the backbone of a laboratory strain (NL4-3), including (a) the clade B consensus variant encoding a serine (underlined) at residue 6 (RTSKA[S]{.ul}LER; RR9), (b) the most common, and putative escape form, in A\*03-positive individuals encoding a proline (underlined) at that position (RTSKA[P]{.ul}LER; RPR9), and (c) a variant containing an amino acid change at one of the HLA-binding anchors at position 9 (underlined; RTSKASLE[G]{.ul}; RG9) to cause the loss of binding capacity to the A\*0301 allele. We anticipated that the consensus variant (RR9) should be recognized by a peptide-specific T cell clone derived from an A\*03-positive individual, whereas the RPR9 would escape from recognition. Similarly, the RG9 variant should be less well recognized because of reduced HLA binding. Importantly, all viral variants were designed to be synonymous in the corresponding regular reading frame. To assess viral inhibition, CD4^+^ T cells were infected with the different viral constructs and coincubated with effector cells, and viral replication was monitored for 7 d of culture. To avoid outgrowth of autologous virus, CD4^+^ T cells from an elite controller were used for these experiments. An A\*03-RR9--specific CD8^+^ CTL clone ([Fig. S1](http://www.jem.org/cgi/content/full/jem.20091808/DC1)) from the same subject was used as an effector cell population and added at different E/T ratios to the infected CD4^+^ cells ([Fig. 4](#fig4){ref-type="fig"}). Even at an E/T ratio of 1:10, \>80% of the viral replication was inhibited at day 7 as compared with infection of target cells alone when virus containing the clade B consensus sequence was used. In contrast, when using the variant virus containing the proline variant (RPR9) or the variant with the change at the anchor position that should abrogate binding of the epitope to HLA-A\*03 (RG9), no relevant inhibition of viral replication was observed. Together with the variant recognition data derived from experiments with PBMCs ([Fig. 3 B](#fig3){ref-type="fig"}), the results obtained in the viral replication inhibition assay strongly suggest that the A\*03-RR9 epitope is indeed expressed, processed, and presented in HIV-infected cells in sufficient amounts to sensitize these cells for CTL-mediated killing.

![**A\*03-RR9--specific CTLs inhibit viral replication.** (A--E) Different virus variants were designed on an NL4-3 backbone (A) using site-directed mutagenesis and were tested in viral inhibition assays. CD4^+^ T cells were infected and co-cultured with an RR9-specific CD8^+^ clone from the same subject at various E/T ratios over 7 d. Viral inhibition was determined by p24 measurement in supernatants at days 3, 5, and 7. The consensus (B) but not the S→P variant (C) was strongly inhibited. Similarly, an R→G mutation at position 9, potentially disrupting MHC class I binding to A\*03, was not inhibited (D). The inhibition of viral replication of the consensus variant was dependent on the E/T ratio (E). One representative out of three independent experiments is shown. Inhibition assays were set up in triplicates.](JEM_20091808_GS_Fig4){#fig4}

Alternative start codon usage may reflect a mechanism of frameshift epitope expression in infected cells
--------------------------------------------------------------------------------------------------------

Different mechanisms leading to the generation of CTL epitopes encoded by ARFs have been described in the literature (for review see [@bib37]). In particular, the presence of upstream alternative splice sites and alternative start codons has been suggested to potentially facilitate the expression of ARF sequences ([@bib12]; [@bib37]; [@bib49]). However, none of these mechanisms that could enable or increase the expression of such frameshifted sequences has been analyzed in HIV/SIV in detail.

Because a known splice acceptor site, SA1, is located right upstream of the RR9 epitope ([@bib1]), we first hypothesized that HIV might be making mistakes when splicing mRNA using this acceptor site. We isolated intracellular HIV mRNA from T cells infected with NL4-3 and amplified putative splice variants by nested RT-PCR using forward primers just upstream of Gag and reverse primers just downstream of HIV integrase. During PCR amplification a short (50-s) elongation time was used to selectively amplify splice variants but exclude amplification of genomic RNA. PCR amplicons were cloned into *Escherichia coli*, and 96 clones were sequenced and analyzed for evidence of alternative splice variants. However, all 96 sequences were identical and exhibited the expected splicing pattern (unpublished data), suggesting that alternative splicing is not the major mechanism of production of the RR9 ARF peptide.

We then investigated if initiation of translation at a start codon in the ARF upstream of the epitope could be a mechanism whereby the ARF peptide is produced in vivo. When the ARF +2 sequence was screened for potential start codons (AUG, methionine), the closest methionine was found \>100 amino acids upstream of the RR9 epitope. However, the potential reading frame after this methionine was not open, as there were five stop codons between the methionine and the RR9 epitope that would abrogate expression. When searching for alternative (nonmethionine) start codons, a leucine residue just 2 amino acid residues upstream of the RR9 epitope ([Fig. 2 A](#fig2){ref-type="fig"}) was identified and found to be extremely conserved in the British Columbia cohort (not depicted). Leucine has previously been described to be able to act as an alternative start codon ([@bib49]). To investigate if the RR9 epitope would indeed be processed and presented from such a short precursor protein and whether this leucine residue in fact acted as an alternative start codon, we designed specific viral variants on the backbone of an NL4-3 virus containing the RR9 epitope. The leucine residue was changed either to a regular start codon (methionine; L→M) or an amino acid that is not described as an alternative start codon (valine; L→V). We hypothesized that if the leucine indeed acts as an alternative start codon for this epitope, the change to a regular start codon would increase its expression and hence its inhibition by a specific T cell clone. On the other hand, the variant with the valine should not be expressed at all and, therefore, we expected to see no inhibition of viral replication at all. These mutations were again carefully designed to be synonymous in the regular reading frame and, therefore, not alter the sequence integrity of the original reading frame ([Fig. 5 A](#fig5){ref-type="fig"}). Using these two viral variants in viral inhibition assays and comparing viral inhibition to the consensus variant, we demonstrated that the L→M variant was strongly inhibited ([Fig. 5 B](#fig5){ref-type="fig"}). Interestingly, this inhibition exceeded the suppression seen with the virus carrying the leucine (0.9 vs. 3.1 log at an E/T ratio of 1:5 at day 7; [Fig. 5 D](#fig5){ref-type="fig"}) and, therefore, suggests that the RR9 epitope is more highly expressed in the context of a regular start codon. On the other hand, the L→V variant was, as expected, not inhibited at all ([Fig. 5 C](#fig5){ref-type="fig"}). Collectively, these data indicate that expression of the alternative leucine is in fact a possible mechanism for RR9 epitope expression in HIV-infected cells.

![**Alternative start codon usage might be a mechanism for frameshift epitope expression of A\*03-RR9.** (A--D) To address if an upstream leucine could figure as a alternative start codon and therefore regulate expression of A\*03-RR9, viral variants carrying a regular start codon (AUG, methionine) or lacking a potential start codon (valine instead of leucine) at this position were created (A). The inhibition of the variants by an RR9-specific CD8^+^ clone was assessed and compared with the consensus variant with the leucine. The L→V variant (C) was no longer inhibited, whereas the L→M variant (B) was more strongly inhibited than the L variant (−3 vs. −1 log at an E/T ratio of 1:10 at day 7), pointing at a potential mechanism for the expression of A\*03-RR9 (D). One representative out of three independent experiments is shown. Inhibition assays were set up in triplicates.](JEM_20091808_GS_Fig5){#fig5}

DISCUSSION
==========

RNA viruses with relatively small genomes, such as HIV, human T lymphocyte virus, hepatitis B virus, and hepatitis C virus, have found ways to increase the genetic information of their genome by encoding essential proteins in different forward or backward reading frames ([@bib29]; [@bib57]; [@bib22]). Through single or double nucleotide deletion or insertions and by the presence of alternative start codons, alternative splice sites, or possibly other mechanisms, highly variable pathogens such as RNA-based HIV and hepatitis C virus may consistently produce frameshifted mRNA sequences, giving rise to alternative viral antigens that may be processed and presented by host HLA molecules. Indeed, two recent reports, one in HIV and one in SIV, indicate that antigens resulting from ARF translation can serve as a source of CTL epitopes against which the host can mount a cellular immune response ([@bib14]; [@bib36]). The present study expanded on these observations and addressed whether and how strongly frameshifted sequences could be under immune selection pressure on a population level. The data also document that common HLA allele--driven epitope variants can be effective CTL escape mutations and can affect CTL recognition of virally infected cells. Finally, a potential mechanism for out-of-frame epitope expression, namely the use of an alternative start codon, is also supported by our data. Collectively, the data provide for the first time evidence that ARF-based epitope sequences cannot only induce immune responses comparable in breadth to those observed against regulatory HIV proteins, but that these HLA-restricted responses specific for an ARF-encoded epitope are also able to inhibit viral replication in vivo. Furthermore, we demonstrate that HLA-restricted immune pressure exerted on ARF peptides is apparently strong enough to drive HIV evolution on a population level. Indeed, within the studied HLA-A\*03--restricted ARF peptide, we document and functionally validate an escape mutation occurring at position 6 of this ARF epitope, which does not affect the coding sequence of HIV integrase. The results are thus consistent with adoptive CTL transfer experiments in mouse retroviral infection and provide human experimental data in support of recent observations in the SIV model ([@bib27]; [@bib36]).

Since the first report of HLA footprints in HIV sequences ([@bib40]), the bioinformatic approaches to identify these imprints have been refined and take HIV founder sequence effects, HLA linkage disequilibrium, and HIV sequence covariation into account ([@bib2]; [@bib15]; [@bib11]). Using such a recently developed refined approach, we identified 64 discrete HLA-driven imprints across the HIV gag, pol, and nef spanning ARF +1 and +2 sequences ([@bib15]). Their distribution across the three proteins ([Table I](#tbl1){ref-type="table"}) is shifted as more ARF imprints were observed in gag and pol regions than in nef, whereas first-frame imprints were more common in Nef ([@bib11]). For the present study, where we focused on the 20 best-supported imprints for peptide synthesis, this led us to test more gag-ARF and pol-ARF than nef-ARF imprints for functional responses ([Table II](#tbl2){ref-type="table"}). Again, compared with analyses in the regular coding frame, this selection is unlikely to have reduced or overestimated the breadth of detectable responses, as the imprints reported in the first frame were located with comparable frequency in previously defined epitopes across the three proteins tested (unpublished data). Also, compared with response rates to regular coding frame--based screenings (i.e., traditional OLP-based tests), the observed frequency of responses to ARF peptides is comparable to the frequency at which regulatory HIV proteins and the HIV protease protein are being targeted ([@bib18]; [@bib61]). The magnitude of responses is, however, clearly below the level that has been observed for regular HIV protein--specific responses ([@bib18]; [@bib61]). As ARF-derived epitopes are probably expressed and presented at a lower density than some of the presumably more abundantly produced immunodominant Gag-derived epitopes, a lower magnitude of the CTL response would not be surprising. In addition, responses with median frequencies as reported in this study are comparable to infections other than HIV, which is known to induce particularly strong responses ([@bib5]). The frequency of responses is also similar to what [@bib14] have reported for a single HLA-B\*07--restricted response in highly active antiretroviral therapy--treated individuals. Their HLA-B\*07--restricted response was, however, not included in our screening, as no HLA-B\*07--associated imprint in the vicinity of the described ARF epitope was identified, possibly either because of a lack of statistical power in our cohort for this allele or because of inconsistent or diverse escape patterns from this response.

A frequent limitation in HLA imprint studies is that effective CTL escape by the observed mutation is assumed rather than experimentally demonstrated. In this study, we assessed variant recognition, both on a peptide basis as well as by expressing variant viral sequences. As the data demonstrate, the common escape variant in position 6 of the RR9 epitope abrogated CTL recognition and control of viral replication. Effective CTL escape by such a mutation that is enriched in individuals expressing the restricting HLA-A\*03 allele lends further strong support to the in vivo relevance of this mutation and the effectiveness of the CTL immune pressure against the RR9 epitope.

HLA footprint analyses can only provide a partial picture of the host immune response to HIV, and it is difficult to judge the in vivo relevance of ARF-derived responses or to estimate its total contribution to the global immune response to HIV from such analyses. Aside from simple statistical considerations, such as insufficient power because of low allele frequency, fixation or near-to-fixation of escape variants in the population, and differential kinetics of reverting mutations, the current analysis is likely to underestimate the true breadth of responses because of several additional reasons. A basic issue is that frameshifts or single nucleotide insertion in the viral genome may occur repetitively, and a final epitope sequence could contain sequences of more than one reading frame. Although some positions in the genome may be more or less frequently affected by frameshifts, it is thus possible that epitopes exist that are encoded by an essentially unpredictably vast array of random mosaic epitope sequences composed of more than one reading frame. The identification of such potential epitopes based on HLA imprints is difficult, as all combinations of possible frameshifts in the vicinity of the imprint would need to be synthesized as test peptides. Despite this potential complexity, however, our data also indicate that HIV-infected cells seem to produce and present ARF-encoded peptides consistently enough across individuals to result in population-based immune pressure reflected as population-wide HLA footprints. Further documentation of how consistently HIV-infected cells may present ARF-encoded peptide sequences may also come from epitope elution studies using HIV-infected cells that may help to identify epitopes with partial sequence matches in different reading frames ([@bib26]).

Apart from statistical power to identify specific HLA allele--associated imprints, ex vivo immune analyses will only reveal responses if they are present in an appreciable number of subjects. Although some of the most immunodominant known HIV epitopes are targeted by \>50% of individuals expressing the respective restricting HLA allele, many responses are found less frequently and are only detected if the test cohorts are massively expanded so that even infrequent alleles are represented several times ([@bib3]). In addition, HLA imprints in ARF that caused a nonsynonymous change in the first, coding frame were excluded in the present study, assuming that the observed change was driven by immune selection pressure against an epitope in the original HIV protein. Although this may usually be the case, it is a conservative assumption and may have underestimated the true frequency of ARF-based CTL targets. On the other hand, it cannot be excluded that specific codon usage and preferred RNA structure for amino acids in the first frame may have driven some changes in the ARF while being synonymous in the regular coding frame.

The in vivo relevance of ARF-encoded epitopes will also depend on the likelihood of and the mechanisms involved in their production in virally infected cells. Data from a recent study suggest the possibility of ribosomal slippage being a potential important mechanism given the RNA structure of HIV ([@bib56]). However, to date, it still remains unclear to what level ARF-derived epitopes in HIV/SIV are a degradation product of functional proteins or RNA sequences encoded by the frameshift or antisense sequence ([@bib39]; [@bib33]), or are rather simply defective ribosomal products that result from accidental frameshift and are rapidly degraded ([@bib60]). The data shown in this study do not resolve this point but indicate that the use of alternative start codons could likely help the production of ARF epitopes, as the replacement of leucine with valine showed an abrogated suppression of viral replication and, presumably, RR9 presentation. Although the substitution of leucine to methionine caused significantly improved suppression of viral replication, the lower level expression of the leucine is probably sufficient to sensitize infected cells for CTL recognition. This is in line with data by [@bib54] showing that a single peptide--MHC complex on a target cell might be sufficient to elicit a cytolytic T cell response. Also, as the relative magnitude of responses and the relative abundance of presented epitopes do not necessarily correlate with in vivo protection ([@bib21]), the expression level of the RR9 epitope and the magnitude of the response are likely not the only factors that determine its in vivo relevance. Regardless of this open question, the present study is the first demonstration of population-wide viral adaptation to immune selection pressure exerted by CTL responses targeting HLA class I--restricted epitopes encoded by HIV frameshifted sequences. These responses lead to effective CTL escape variants in vivo and were able to inhibit viral replication in vitro. Thus, they show all the characteristics that are commonly seen as important attributes of an effective HIV-specific CTL immunity and may be considered for inclusion in HIV vaccine design.

MATERIALS AND METHODS
=====================

### Ethical approval.

The study was approved by the respective local ethics boards (Partners Institutional Review Board and Providence Health Care/University of British Columbia Research Ethics Board).

### Virus sequencing and HLA typing.

Plasma RNA from 765 treatment-naive, chronic, predominantly HIV clade B--infected (97.5%) subjects enrolled in the British Columbia HOMER Study was isolated and sequenced as previously described ([@bib28]). In brief, HIV RNA was extracted from a pretherapy plasma sample and HIV gag, protease, RT (codons 1--400), integrase, and nef were amplified using nested RT-PCR and bulk sequenced on an automated DNA sequencer (ABI 3700; Applied Biosystems). For all genes, data on at least 500 individuals were available (gag, *n* = 567; protease/RT, *n* = 532; integrase, *n* = 582; and nef, *n* = 686). HLA class I typing was performed by sequence-based typing as previously described ([@bib9], [@bib10]). Accession numbers of the sequences are listed in the respective publications ([@bib9], [@bib10]).

### Identification of HLA-associated amino acid variation in HIV genomes.

Gag, Pol, and Nef sequences were aligned to HXB2 and translated into the frameshifted reading frames +1 and +2. HLA-associated polymorphisms in the frameshifted sequences were identified using previously published, phylogenetically informed methods, which additionally correct for HLA linkage disequilibrium as well as HIV codon covariation ([@bib15]). Statistical significance is reported using q-values, which estimate the false discovery rate for each comparison ([@bib52]). We used a threshold of q ≤ 0.2, meaning that we expect a false-positive proportion of 20% among identified associations. To avoid identifying false-positive HLA associations in ARFs that could reflect immune pressure on the regular ORF, all HLA associations in the +1 and +2 ORFs were excluded when they were (a) associated with a nonsynonymous change at the same position in the first frame, (b) had an imprint for any other allele within ±2 amino acids in the original reading frame, or (c) had a known optimal epitope in the original reading frame that was restricted by the same HLA allele for which the imprint was observed for the ARF. In addition, all regions with imprints in the +1 and +2 ORFs that had a length of \<10 amino acids between two stop codons were excluded from further analysis because of a low probability that these epitopes were in fact expressed all the way in the same frame and would hence not be discovered by a peptide screen.

### Assessment of T cell responses to frameshift-derived epitopes.

To test for immune responses to ARF epitopes, 85 untreated chronically HIV-infected individuals were recruited from hospitals in the Boston area. 32 HIV-negative individuals were included as controls. From all individuals, fresh PBMCs were isolated from whole blood using density gradient centrifugation and used in direct ex vivo ELISPOT assays as previously described ([@bib18]). In brief, 100,000 fresh PBMCs were incubated with peptides in pools of four peptides at a final concentration of 28 µg/ml in 96-well polyvinylidene difluoride plates (Millipore) precoated with the anti--IFN-γ mAb 1-D1K (Mabtech) according to the manufacturer's instructions. A positive (PHA) and at least four negative (no peptide) controls were included for each individual tested. ELISPOT results were expressed as SFCs/10^6^ input cells. The threshold for a positive response was defined as at least 50 SFCs/10^6^ input cells and responses exceeding three times the mean of negative wells. Peptides were synthesized as listed in [Table II](#tbl2){ref-type="table"}. Specific epitopes with an HLA-binding motif for the observed imprint were predicted using epitope prediction algorithms (available at <http://atom.research.microsoft.com/bio/epipred.aspx> \[[@bib25]\] and [www.hiv.lanl.gov/content/immunology](www.hiv.lanl.gov/content/immunology)). In brief, for each HLA-associated polymorphism, a consensus sequence was constructed from sequences that contained the predicted nonadapted form of the association, and Epipred was used to predict the likeliest epitope (9--11mer) within a window extending ±13 amino acids from the observed HLA-associated polymorphism or until the first consensus stop codon. In cases where the imprint was not included in the predicted epitope, OLPs of 17--18 amino acids in length were designed and included in the screening ([Fig. 1 C](#fig1){ref-type="fig"}).

### Determination of the functional avidity and HLA restriction analyses.

The optimal epitope length was determined using sequential peptide truncations in serial 10-fold dilutions ranging from 100 to 0.0001 µg/ml ([@bib19]). Freshly isolated or frozen, unexpanded PBMCs were used in standard IFN-γ ELISPOT assays. The functional avidity, defined as the antigen dose needed to elicit a concentration indicating half-maximal response (SD50%), was determined. The shortest peptide with the lowest SD50% was considered the optimal epitope ([@bib20]). HLA restriction was determined using standard ELISPOT assays and epitope-specific TCLs. TCLs were used for restriction analysis after 10--14 d of peptide-specific in vitro expansion. EBV-transformed, partly HLA-matched B cell lines (BCLs) were used as APCs for restriction analysis, as previously described ([@bib24]). BCLs were incubated for 1 h with the optimal peptides at 20 µg/ml, followed by extensive washing. BCLs without peptide were used as negative controls. Peptide-specific TCLs (E/T ratio of 1:1) and 2 µg/ml of anti-CD28 and -CD49d co-stimulatory antibodies (BD) were added and incubated for 6 h at 37°C. For the last 5 h of incubation, 10 µg/ml Brefeldin A was added. Cells were fixed and permeabilized using Cytofix/Cytoperm (BD) according to the manufacturer's instructions, and the percentage of responding cells was determined using anti-CD3--PerCP, anti-CD4--PE, anti-CD8--allophycocyanin, and anti--IFN-γ--FITC antibodies (all from BD).

### Viral variants expressing escape mutations and artificial start codons in ARFs.

Viruses harboring single or multiple point mutations in ARFs within and/or surrounding the A\*03-RR9 epitope were created on an NL4-3 backbone using site-directed mutagenesis (QuikChange XL; Agilent Technologies) according to the manufacturer's instructions. The viral variants generated and used in in vitro inhibition assays are summarized in [Fig. 4 A](#fig4){ref-type="fig"} and [Fig. 5 A](#fig5){ref-type="fig"}. Importantly, mutagenesis primers were designed to only cause synonymous changes in the primary ORF, meaning that the engineered point mutations did not disrupt the regular reading frame. NL4-3 contains the sequence of the escape variant (RTSKA[P]{.ul}LER). Therefore, we first created a virus variant that carries the clade B consensus sequence. Based on this P→S variant, the other viruses were created. The following primer sequences were used: P→S variant, 5′-CCAGTTTGGA­AAGGACCAGCA­AAGCTTCTCTG­GAAAGGTGAAG­GGGCAGTAG-3′ and 5′-CTACTGCCCC­TTCACCTTTCC­AGAGAAGCTTT­GCTGGTCCTTT­CCAAACTGG-3′; R→G variant, 5′-CCAGTTTGGA­AAGGACCAGCA­AAGCTTCTCTG­GAGGGTGAAGG­GGCAGTAGTAA­TACAAG-3′ and 5′-CTTGTATTAC­TACTGCCCCTT­CACCCTTCCAG­AGAAGCTTTGC­TGGTCCTTTCC­AAACTGG-3′; L→M variant, 5′-TTATTACAGG­GACAGCAGAGA­TCCAGTATGGA­AAGGACCAGCA­AAGCTTCTCTG­GAAAGGT-3′ and 5′-ACCTTTCCAG­AGAAGCTTTGC­TGGTCCTTTCC­ATACTGGATCT­CTGCTGTCCCT­GTAATAA-3′; and L→V variant, 5′-TTTATTACAG­GGACAGCAGAG­ATCCAGTGTGG­AAAGGACCAGC­AAAGCTTCTCT­GGAAAGGT-3′ and 5′-ACCTTTCCAG­AGAAGCTTTGC­TGGTCCTTTCC­ACACTGGATCT­CTGCTGTCCCT­GTAATAAA-3′.

### In vitro inhibition of viral replication.

Viral inhibition assays were performed as described previously ([@bib58]). In brief, autologous CD4^+^ T cells were used as target cells after expansion from PBMCs using 1 µg/ml of a bispecific anti-CD3/8 mAb in R10-50 media (RPMI 1640 media supplemented with 10% fetal calf serum, 1% [l]{.smallcaps}-glutamine, and 50 U/ml IL-2) for 5 d ([@bib16]). Cells were used without further CD4 separation for infection with the respective viruses. Infection was performed by incubating CD4^+^ T cells for 4 h with the different HIV stocks at a multiplicity of infection of 0.01 followed by extensive washing. 100,000 target cells were added per well of a round-bottom 96-well plate and incubated with an A\*03-RR9--specific CD8^+^ clone at E/T ratios of 1:1, 1:5, 1:10, and 1:50. Cells were co-cultured for 7 d in 200 µl R10-50. At days 3, 5, and 7, 100 µl of the supernatant was replaced by fresh media. p24 was quantitated by a standard quantitative ELISA (commercial kit; Dupont) according to the manufacturer's instructions and as described previously ([@bib7]; [@bib31]; [@bib16]).

Epitope-specific T cell clones were generated from a peptide-specific TCL by selection of epitope-specific CD8^+^ T cells using an IFN-γ capture assay according to the manufacturer's instructions (Miltenyi Biotec) followed by live single-cell sorting of CD3^+^ CD8^+^ CD14^−^ CD19^−^ IFN-γ^+^ cells on a FACSAria (BD) using a 70-µm nozzle at 70 psi. The single-sorted cells were expanded on irradiated feeder cells with 0.5 µg/ml of an anti-CD3 antibody (12F6; [@bib31]) in R10-50. Flowcytometric polyfunctionality stainings (as described in [@bib4]) showed that the cells produced IFN-γ (\>85%), TNF (\>95%), and MIP-1β (\>99%) and expressed CD107a (\>98%; Fig. S1).

### Online supplemental material.

Table S1 provides the complete list of individual HLA associations with HIV sequence polymorphisms with a q-value \<0.2, independent of their respective location in relation to associations seen in the primary ORF. Tables S2 and S3 provide HLA types of the HIV-infected and -uninfected individuals, respectively, included in the study. Fig. S1 shows the intracellular cytokine staining of an A\*03-RR9--specific CD8^+^ T cell clone derived from single-cell sorting in response to stimulation with A\*03-RR9 peptide. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20091808/DC1>.
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